Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price reached a new 52-week high on Monday . The company traded as high as GBX 14 and last traded at GBX 13.53, with a volume of 4944059 shares traded. The stock had previously closed at GBX 13.20.
Scancell Stock Performance
The stock has a market capitalization of £140.36 million, a PE ratio of -10.73 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The stock has a fifty day moving average of GBX 10.48 and a 200-day moving average of GBX 10.12.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Your Signature Is Missing – Act Before It’s Too Late
- What Expenses Can Be Deducted From Capital Gains Tax?
- Punch these codes into your ordinary brokerage account
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Buy This Stock at 9:30 AM on MONDAY!
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
